MedTrace Logo

Efficacy of Atorvastatin as Adjunctive Treatment for Chronic Plaque Type Psoriasis

NCT02432040 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2015-11-23

Study results available
· View outcomes & findings →

Summary

This study aimed to assess the efficacy and safety of atorvastatin 40 mg/day as an adjunct to betamethasone valerate 0.1% ointment applied twice daily in the treatment of patients with mild to moderate chronic plaque type psoriasis, as determined by mean reduction in PASI scores. Specific objectives included the determination and comparison of the absolute number and proportion of patients who achieved PASI-50 and the mean reductions in lipid profile (total cholesterol, HDL, LDL, triglycerides) and high-sensitivity C-reactive protein (hsCRP) measured from baseline and every month thereafter up to 6 months of treatment. This study also investigated the impact of atorvastatin treatment on the patients' quality of life as well as the association of clinical response to the lipid-lowering and anti-inflammatory effects of atorvastatin.

Conditions

Interventions

DRUG

Atorvastatin

Atorvastatin is a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor used to treat dyslipidemia

DRUG

Placebo

Placebo tablets, made to look like the interventional drug

Sponsors & Collaborators

  • Philippine Dermatological Society

    lead NETWORK

Principal Investigators

  • Sharlene H Chua, Medicine · University of the Philippines-Philippine General Hospital Section of Dermatology

  • Ma. Lorna F Frez, Medicine · University of the Philippines-Philippine General Hospital Section of Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-10-31
Completion
2013-11-30

Countries

  • Philippines

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02432040 on ClinicalTrials.gov